Hysterosalpingography

Boston IVF Welcomes Dr. Meaghan Delaney to its Springfield Fertility Center, Expanding Access to Expert Care in Western Massachusetts

Retrieved on: 
Tuesday, February 20, 2024
Boston University, Texas Children's Hospital, IUI, Hysterosalpingography, Medicine, MD, Telehealth, Semen analysis, IVF, Fertility, PCOS, REI, Patient, Pioneer Valley, Family, Medical Center, HSG, Birth control

SPRINGFIELD, Mass., Feb. 20, 2024 /PRNewswire-PRWeb/ -- Boston IVF, one of the world's most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986, is pleased to announce the addition of reproductive endocrinologist, Dr. Meaghan Delaney, MD to its new fertility center in Springfield, MA.

Key Points: 
  • The addition of Dr. Meaghan Delaney to Boston IVF and its fertility clinic in Springfield enhances the accessibility of prompt reproductive care for those desiring to build a family.
  • "Dr. Delaney's return to western Massachusetts and commitment to patient well-being ensure seamless care, delivering invaluable advantages to our patients," stated David Stern, CEO of Boston IVF.
  • Dr. Delaney transitions to Boston IVF from her position as the Medical Director at the UMass Memorial Fertility Center in Worcester, MA.
  • "Dr. Delaney's return to western Massachusetts and commitment to patient well-being ensure seamless care, delivering invaluable advantages to our patients," stated David Stern, CEO of Boston IVF.

Rejuvenating Fertility Center Updates Its IVF Plus Program and its Financing Options Amid Inflation

Retrieved on: 
Tuesday, March 7, 2023
Transfer, LendingClub, Ozone, Patient, Freezing, PCOS, Infertility, Hysterosalpingography, Risk, Fertility, Fertilisation, Lipid emulsion, Male, HSG, PRP, RFC, Polycystic disease, Woman, Cryopreservation, ICSI, Platelet-rich plasma, PGT, Diagnosis, Genetic testing, Polycystic ovary syndrome, Family, IVF, STD, Semen analysis, SIS, Pregnancy, FET, Birth control, Mineral oil

The comprehensive IVF treatment program at Rejuvenating Fertility Center covers three cycles to be completed within 9 months from the start of the first cycle.

Key Points: 
  • The comprehensive IVF treatment program at Rejuvenating Fertility Center covers three cycles to be completed within 9 months from the start of the first cycle.
  • With the IVF + Guaranteed Program at RFC, cycle monitoring will be covered when performed at the center.
  • RFC also introduces new financing options in response to inflation:
    CapexMD is known for offering financing options for all types of fertility treatments.
  • Rejuvenating Fertility Center is a medical center specializing in the field of reproductive endocrinology and infertility.

Guerbet: 2023 Strategic Priorities

Retrieved on: 
Monday, January 16, 2023
Prostate cancer, European Medicines Agency, Algorithm, Face, HSG, Hysterosalpingography, Liver, X-ray, Environment, Watson (computer), Microparticle, Research, Google Images, Lymphogram, IBM Watson Health, Intellectual property, Iodine, Growth, Lipiodol, Intelligence, Liver cancer, MRI, Investment, Acquisition, EMA, Risk management, Medical imaging, Guerbet, Mer (software distribution)

Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.

Key Points: 
  • Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.
  • In Europe, the European Medicines Agency (EMA) review is expected in the second half of the year.
  • Guerbet also plans to divest the Occlugel technology acquired in 2018, including several ranges of microspheres for use in embolization.
  • Guerbet ultimately aims to enable the development of a major player in artificial intelligence applied to medical imaging in oncology.

Global Infertility Diagnosis and Treatment Market 2022-2028: Surging Consumption of Tobacco Products Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, November 18, 2022
Health, Other Health, Diagnosis, Semen analysis, Infertility, Artificial insemination, ART, IUI, Hysteroscopy, Female, Hysterosalpingography, Medicine, ICSI, Tobacco, Woman, Reproductive technology, Medical tourism, Growth, Fertilisation, Fertility, Male, Smoking, Genetic testing, Medical device, Birth control

The global infertility diagnosis and treatment market is anticipated to grow at a substantial CAGR of 7.0% during the forecast period.

Key Points: 
  • The global infertility diagnosis and treatment market is anticipated to grow at a substantial CAGR of 7.0% during the forecast period.
  • The growth of the global infertility diagnosis and treatment market during the forecast period can be attributed to the increase in the level of smoking.
  • The global infertility diagnosis and treatment market is segmented based on diagnosis and treatment.
  • Global Infertility Diagnosis and Treatment Market Research and Analysis by Infertility Treatment.

Minimally invasive treatment could allow more women to conceive without fertility treatments

Retrieved on: 
Tuesday, June 14, 2022
Woman, Interventional radiology, University of Texas Health Science Center Department of Radiology, Hysterosalpingography, Machan, Infertility, Research, Fertility, Society of Interventional Radiology, Private practice, Society, HSG, University, Female, Multimedia, Mucus, Physician, Radiology, Health, SIR, Student, Tubing (recreation), Diagnosis, MD, Department, Hospital, Medical imaging, Birth control

FAIRFAX, Va., June 14, 2022 /PRNewswire/ -- A simple diagnostic procedure, followed by an interventional radiology treatment known as fallopian tube recanalization, could allow a high percentage of women struggling with infertility from blocked fallopian tubes to conceive with less involved or, in some cases, no further invasive fertility procedures, according to new research presented at the Society of Interventional Radiology Annual Scientific Meeting. Researchers said that most women with with blocked fallopian tubes could have their condition easily corrected.

Key Points: 
  • "This procedure and treatment can help women make an informed decision about infertility treatments.
  • "As women increasingly desire more thorough discussions of available options and input into their medical care, they appreciate detailed information to help them make choices.
  • The women then underwent a selective salpingography to confirm their HSG diagnosis and, if needed, underwent fallopian tube recanalization.
  • "Fertility treatments can be expensive and out of reach for many women," he said.